Filing Flows › Aurinia Pharmaceuticals (AUPH) › R&D spending
Aurinia Pharmaceuticals (AUPH) R&D spending by quarter
Aurinia Pharmaceuticals' R&D spending was $7.5M in Q1 2026 (first quarter 2026), -11% from Q3 2025. Over the last 4 quarters it ranged from $5.7M (Q1 2025) to $8.4M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $7.5M | -11% | +30% |
| Q3 2025 | $8.4M | +13% | — |
| Q2 2025 | $7.4M | +29% | — |
| Q1 2025 | $5.7M | — | — |
Q1 2026 at a glance
Aurinia Pharmaceuticals, Q1 2026: revenue $77.7M (+24% year over year), operating margin 53.3%, net earnings $34.4M, operating cash flow $32.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aurinia Pharmaceuticals' R&D spending?
Aurinia Pharmaceuticals' R&D spending was $7.5M in Q1 2026 (first quarter 2026), -11% from Q3 2025.
How has Aurinia Pharmaceuticals' R&D spending changed?
Over the last 4 quarters it ranged from $5.7M (Q1 2025) to $8.4M (Q3 2025).
Q1 2026 results → · How Aurinia Pharmaceuticals makes money →